BIOLASE (BIOL) Scheduled to Post Earnings on Thursday

BIOLASE (NASDAQ:BIOL – Get Rating) is scheduled to release its earnings data after the market closes on Thursday, May 12th. BIOLASE has set its FY 2022 guidance at EPS and its Q1 2022 guidance at EPS.

BIOLASE (NASDAQ:BIOL – Get Rating) last released its earnings results on Thursday, March 17th. The medical technology company reported ($0.75) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.75). BIOLASE had a negative net margin of 41.23% and a negative return on equity of 62.78%. The company had revenue of $12.41 million during the quarter. During the same quarter in the previous year, the company earned ($1.75) EPS.

BIOL stock opened at $5.58 on Thursday. The company has a market cap of $34.43 million, a price-to-earnings ratio of -2.03 and a beta of 1.64. The company has a 50 day moving average of $10.18 and a two-hundred day moving average of $10.74. The company has a quick ratio of 2.63, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. BIOLASE has a 12-month low of $4.21 and a 12-month high of $23.49.

A number of research analysts have recently weighed in on the stock. Maxim Group assumed coverage on shares of BIOLASE in a report on Friday, March 18th. They set a “buy” rating and a $37.50 price target on the stock. Colliers Securities restated a “buy” rating on shares of BIOLASE in a report on Tuesday, March 22nd. Finally, StockNews.com assumed coverage on shares of BIOLASE in a report on Thursday. They set a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BIOLASE currently has a consensus rating of “Buy” and an average price target of $43.75.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Morgan Stanley bought a new position in BIOLASE in the 1st quarter worth $34,000. Jane Street Group LLC bought a new position in BIOLASE in the 3rd quarter worth $26,000. Citadel Advisors LLC raised its holdings in BIOLASE by 334.0% in the 3rd quarter. Citadel Advisors LLC now owns 87,626 shares of the medical technology company’s stock worth $56,000 after acquiring an additional 67,437 shares during the period. Two Sigma Investments LP raised its holdings in BIOLASE by 76.9% in the 3rd quarter. Two Sigma Investments LP now owns 192,559 shares of the medical technology company’s stock worth $123,000 after acquiring an additional 83,682 shares during the period. Finally, Geode Capital Management LLC raised its holdings in BIOLASE by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,323,471 shares of the medical technology company’s stock worth $846,000 after acquiring an additional 114,432 shares during the period. Hedge funds and other institutional investors own 11.38% of the company’s stock.

BIOLASE Company Profile (Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

See Also